Резюме
Определение
Анамнез и осмотр
Ключевые диагностические факторы
- presencia de factores de riesgo
- amenorrea u oligomenorrea
- infertilidad
- galactorrea
- pérdida del deseo sexual (libido)
- disfunción eréctil
- deterioro visual (p. ej., hemianopsia temporal)
Другие диагностические факторы
- osteoporosis
- oftalmoplejía
- cefaleas
Факторы риска
- predisposición genética (p. ej., presencia de una mutación que causa el síndrome de neoplasia endocrina múltiple tipo 1 [MEN-1] o adenoma hipofisario hereditario aislado [FIPA])
- terapia con estrógenos
- sexo masculino, de 30 a 60 años de edad
- sexo femenino, de 20 a 50 años de edad
Диагностические исследования
Исследования, которые показаны в первую очередь
- prolactina sérica
- resonancia magnética (IRM) hipofisaria
- examen computarizado del campo visual
Алгоритм лечения
mujeres en la etapa de la premenopausia
mujeres en la etapa de la posmenopausia
hombres
Составители
Авторы
Niamh Martin, MB ChB, PhD, FRCP
Reader in Endocrinology
Imperial Centre for Endocrinology
Department of Metabolism, Digestion and Reproduction
Imperial College London
London
UK
Раскрытие информации
NM declares that she has no competing interests.
Выражение благодарностей
Dr Niamh Martin would like to gratefully acknowledge Dr Ilan Shimon, the previous contributor to this topic.
Раскрытие информации
IS receives consultancy and lecturing fees from Pfizer, Israel, and is an author of a number of references cited in this topic.
Рецензенты
Mark Molitch, MD
Professor
Division of Endocrinology
Northwestern University Feinberg School of Medicine
Chicago
IL
Раскрытие информации
MM is an author of a number of references cited in this topic.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Список литературы
Основные статьи
Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021 Dec;50(4):104080.Полный текст Аннотация
Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Полный текст Аннотация
Xia MY, Lou XH, Lin SJ, et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):50-61. Аннотация
Статьи, указанные как источники
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Отличия
- Macroadenomas hipofisarios no funcionales
- Hiperprolactinemia inducida por fármacos
- Hipotiroidismo primario
Больше ОтличияРекомендации
- Position statement for clinical practice: prolactin-secreting tumors
- ACR appropriateness criteria: neuroendocrine imaging
Больше Рекомендации
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer